Results 61 to 70 of about 22,409 (253)

Cutaneous Polyarteritis Nodosa

open access: yes, 2010
Cutaneus polyarteritis nodosa is a variant of polyarteritis nodosa (PAN), without visceral involvement and with a more favourable prognosis. The presence of nodules, located in the lower legs are the most frequent cutaneous lesion.
KONTAŞ, OLGUN   +5 more
core   +1 more source

Cutaneous polyarteritis nodosa : case report [PDF]

open access: yes, 2006
Poliarterite nodosa cutânea é vasculite que acomete vasos de médio calibre na derme profunda e panículo adiposo. É caracterizada por nódulos dolorosos que podem ulcerar, antecedidos, acompanhados ou seguidos de livedo reticular, sendo seu diagnóstico ...
Nogueira, Lucas Souza Carmo   +1 more
core   +1 more source

The spectrum of cutaneous polyarteritis nodosa. A case report of two contrasting cases and review of the literature

open access: yesClinical Case Reports, 2022
Cutaneous polyarteritis nodosa is a rare neutrophilic vasculitis. We present two cases that reflect the gamut of this disorder including one case whose delayed diagnosis led to permanent nerve deficit and scarring.
Ian Liang   +3 more
doaj   +1 more source

Rare Gain‐of‐Function Variants in IDH1 and IDH2 Confer Increased Risk of Immune‐Mediated Rheumatic Diseases

open access: yesACR Open Rheumatology, Volume 8, Issue 4, April 2026.
Objective Gain‐of‐function variants in IDH1 and IDH2 are enriched among individuals with coexisting myeloid neoplasms and autoimmune diseases. However, the association between IDH1/IDH2 variants and rheumatic diseases independent of hematologic neoplasms remains unclear. We investigated the association between rare gain‐of‐function and loss‐of‐function
Mahmut S. Kaymakci   +3 more
wiley   +1 more source

Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?

open access: yesRMD Open, 2017
We describe the effect of interleukin 6 (IL-6) blockade using tocilizumab (TCZ) for inducing and maintaining remission of refractory polyarteritis nodosa (PAN).
A. Saunier   +5 more
semanticscholar   +1 more source

Do Not Anchor on Vasculitis: Pancreatic Cancer Presenting With Isolated Celiac/Superior Mesenteric Artery Thickening

open access: yesACR Open Rheumatology, Volume 8, Issue 4, April 2026.
Objective Medium‐vessel vasculitis involving the visceral vasculature in adults is rare. Pancreatic ductal adenocarcinoma (PDAC) has been implicated in medium artery vascular thickening secondary to extravascular migratory metastasis with involvement of the celiac and superior mesenteric vessels.
Maryam Own   +2 more
wiley   +1 more source

Edoxaban‐induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
Abstract Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has not been established as a distinct clinical entity.
Katsuya Endo   +8 more
wiley   +1 more source

Chronic polyarthritis as the first manifestation of childhood systemic polyarteritis nodosa

open access: yesEinstein (São Paulo)
Arthritis has been reported as an acute pattern, generally evanescent with oligoarthritis, mostly affecting knees and ankles in childhood systemic polyarteritis nodosa.
Glaucia Vanessa Novak   +5 more
doaj   +1 more source

Cutaneous polyarteritis nodosa: A case report with a brief review of literature

open access: yesMedical Journal of Dr. D.Y. Patil University, 2013
Polyarteritis nodosa (PAN) is a rare vasculitis with multisystem involvement. The definition, diagnostic criteria and validity of cutaneous polyarteritis nodosa (c-PAN) as a variant of classic PAN limited to skin have continued to remain disputed.
Yugal K Sharma   +3 more
doaj   +1 more source

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy